Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
49 Hypertension Trials near Overland Park, KS
Power is an online platform that helps thousands of Hypertension patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerGlucose and Fat Impact on Vascular Health
Kansas City, Kansas
The purpose of our study is to understand the extent to which the blood vessels are affected by glucose and fat (lipids) in lean healthy adults and if these changes in the blood vessels contribute to the development of high blood pressure.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Key Eligibility Criteria
Disqualifiers:Diabetes, Smoking, Hyperlipidemia, Hypertension, Heart Disease, Others
Must Not Be Taking:Vitamin C, Vitamin E, Omega-3
46 Participants Needed
Pranayama for Hypertension in Pregnancy
Merriam, Kansas
Slow deep breathing actives the vagal nerve and leads to a natural reduction in physiological parameters such as blood pressure, heart rate and digestion. The effects of these techniques have not been assessed in pregnancy. The primary objective is to assess the effects of various yogic deep breathing techniques on blood pressure during pregnancy. The breathing exercises will include Alternate nostril breathing, Bhramari breathing, and Sheetali breathing. A secondary objective will be to assess the effects of these breathing exercises on other physiological parameters including heart rate, heart rate variability, body temperature, cardiac output, vascular resistance and respiratory rate.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Sex:Female
Key Eligibility Criteria
Disqualifiers:Unstable Maternal Condition, Severe Pulmonary Disease, Others
90 Participants Needed
Anti-inflammatory Drugs for Obesity
Kansas City, Kansas
This trial tests if taking clonidine for a short period can reduce inflammation in patients with high nerve activity. Clonidine calms these nerves, potentially lowering blood pressure and inflammation.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Heart Disease, Neurological Disorders, Transplant, Others
Must Not Be Taking:Clonidine, Beta-blockers, Hypertension Meds
60 Participants Needed
Lorundrostat for High Blood Pressure
Kansas City, Missouri
This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breast-feeding, Others
Must Not Be Taking:Prohibited Medications
1400 Participants Needed
Vitamin C for Insulin Resistance
Kansas City, Kansas
This trial is testing if Vitamin C can improve blood vessel health and lower blood pressure in obese adults who have difficulty processing sugar. These individuals often have high blood pressure and a higher risk of heart disease. Vitamin C might help by making blood vessels healthier and calming the nerves that control them. Vitamin C has been studied for its potential benefits in reducing blood pressure and improving heart health, though results have been inconsistent.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:35 - 65
Key Eligibility Criteria
Disqualifiers:Diabetes, Hyperlipidemia, Hypertension, Heart Disease, Others
Must Not Be Taking:Statins, Antihypertensives
23 Participants Needed
Remote Monitoring and Telehealth for High Blood Pressure
Kansas City, Kansas
This is a randomized, controlled, pragmatic trial designed as a "type I hybrid effectiveness-implementation trial" that tests a hypertension program integrating a virtual Collaborative Care Clinic (vCCC), home blood pressure monitoring, and telehealth for lowering blood pressure (BP) in two health systems.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:65+
Key Eligibility Criteria
Disqualifiers:Dementia, Hospice, Chemotherapy, Dialysis, Others
1000 Participants Needed
Renal Denervation for High Blood Pressure
Kansas City, Missouri
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Diabetes, Cardiovascular Events, Pregnancy, Others
225 Participants Needed
Lorundrostat for High Blood Pressure
Kansas City, Missouri
This trial tests lorundrostat, a medication that lowers blood pressure by blocking an enzyme involved in hormone production. It targets patients with high blood pressure not controlled by 2 to 5 other medications.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Age:19+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Not Listed
1083 Participants Needed
NCX 470 for Glaucoma
Kansas City, Missouri
This trial is testing NCX 470 eye drops to see if they can safely and effectively lower eye pressure in people with high eye pressure or glaucoma. The goal is to protect their vision by reducing the pressure inside their eyes. NCX 470 is a nitric oxide (NO)-donating bimatoprost with clinically demonstrated pressure-lowering effects.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Narrow Angles, Ocular Disease, Surgery, Others
696 Participants Needed
Inhaled Treprostinil for Pulmonary Arterial Hypertension
Kansas City, Kansas
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Pregnancy, Lung Transplant, Others
92 Participants Needed
Sotatercept for Pulmonary Hypertension
Kansas City, Kansas
This trial tests sotatercept, a medication aimed at improving heart and lung function in adults with a specific type of heart failure. It works by reducing resistance in lung blood vessels, helping the heart pump blood more easily.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:PH WHO Group 1, Lung Disease, Cardiovascular, Others
Must Not Be Taking:PAH-specific Therapies
164 Participants Needed
Levosimendan for Pulmonary Hypertension with Heart Failure
Kansas City, Kansas
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:PH WHO Groups 1, 3, 4, Others
230 Participants Needed
HS135 for Heart Failure and Pulmonary Hypertension
Kansas City, Missouri
A Study of HS135 for the Treatment of in Obese Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Decompensated Heart Failure, Uncontrolled Hypertension, Others
30 Participants Needed
External Lumbar Drainage for Traumatic Brain Injury
Kansas City, Kansas
The goal of this phase 1 randomized controlled safety and feasibility clinical trial are to determine the safety of external lumbar drainage (ELD) in select patients with severe Traumatic Brain Injury (TBI). The main questions it aims to answer are (i) if ELD is feasible and (ii) safe to perform in severe TBI patients who have radiological evidence of patent basal cisterns and midline shift \<5mm without increasing the risk of neurological worsening or cerebral herniation.
All participants will receive routine usual care. The study group will additionally have ELD for cerebrospinal fluid (CSF) drainage. A comparison will be made between the usual treatment plus ELD (interventional) groups, and the usual treatment (control) groups on incidence rate of neurological worsening or cerebral herniation events, and whether total hours with raised intracranial pressure (ICP) are different.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Pregnancy, Prisoners, Severe Spinal Deformity, Others
Must Not Be Taking:Anticoagulants, Anti-thrombotics
30 Participants Needed
Treprostinil Palmitil for Pulmonary Arterial Hypertension
Kansas City, Kansas
This trial is testing an inhalable medicine called TPIP to see if it can help people with high blood pressure in their lungs by making it easier for blood to flow through their lung arteries.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Not Listed
102 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Kansas City, Kansas
This trial is testing sotatercept, a new medication, to see if it can help people with a specific type of high blood pressure in the lungs (PAH) when added to their usual treatment. The study focuses on patients who are newly diagnosed and at higher risk of their condition worsening. Sotatercept aims to reduce the pressure in the lung's blood vessels, potentially slowing down disease progression. Sotatercept has shown significant reduction in pulmonary vascular resistance and maintained clinical efficacy in previous studies.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Not Listed
444 Participants Needed
KER-012 for Pulmonary Arterial Hypertension
Kansas City, Kansas
This trial is testing KER-012, a new injectable medication, in adults with a specific type of high blood pressure in the lungs. The goal is to see if it can lower lung blood pressure and help patients walk better.
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
113 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Kansas City, Kansas
This trial is testing sotatercept added to current treatments for patients with severe PAH who are at high risk of death. The goal is to see if it can lower lung blood pressure and improve patient outcomes. Sotatercept, which modulates bone morphogenic protein receptor type 2 (BMPR2) signaling, showed promising results in earlier studies.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
172 Participants Needed
Inhaled Vardenafil for Pulmonary Arterial Hypertension
Kansas City, Kansas
This trial is testing an inhaled medication called RT234. It aims to help people with pulmonary arterial hypertension (PAH) breathe better and exercise more easily. The medication works by widening the blood vessels in the lungs, making it easier for the heart to pump blood. RT234 is being developed to improve exercise tolerance and symptoms in patients with PAH.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
42 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Kansas City, Kansas
This trial is testing sotatercept, a medication for high blood pressure in the lungs, in adults with PAH who have completed earlier studies. It aims to see if the medication is safe and effective over a long period. Sotatercept helps lung blood vessels function better, reducing lung pressure. Sotatercept has shown promising results in earlier studies for reducing lung pressure and improving exercise tolerance in patients with pulmonary arterial hypertension (PAH).
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, Missed Doses, Others
Must Be Taking:PAH Therapy
815 Participants Needed
Why Other Patients Applied
"My ejection fraction is now 20-25%, quite low. Trying to optimize my medications at this time. I have had Biventricular pacemaker/ICD since 2007. I am doing everything I can to improve my health. Following a diet, exercising 30 minutes every day. Most days my systolic blood pressure is < 100. I had a L/R Cath in December and do not have any problems with my coronary arteries. I'm hoping to learn more about the latest research and drugs by participating in a trial. "
WB
Heart Failure PatientAge: 66
"I've been diagnosed with type 2 diabetes since 2000. I was on the highest dose of metformin, which didn't work for me. In 2022, I tried Ozempic, which had bad side effects. I'm not currently on anything to treat my diabetes, given my experiences (as well as some insurance denials). I'm glad that clinical trials exist to help me try to access the latest research. I'm frustrated but also motivated."
PL
Diabetes PatientAge: 53
"In December 2023 I had a stent placed in an artery. I was so glad that the blockage was found before I had either a heart attack, stroke, or both. I have been on Pravastatin for as long as I can remember but I continue to have elevated cholesterol levels. I'm trying to get ahead of my condition by learning more about the latest research and drugs available."
AQ
Hypercholesterolemia PatientAge: 57
"I have a known blockage developing in lower left main 50%, which my doctors are watching. We've considered surgery, but I'd like to rule out all possible other options first. I've done some research, which brought me to clinical trials."
PA
Artery Disease PatientAge: 64
"I have gasteroparesis which causes me extreme bloating, pain, acid reflux, occasional vomiting, nausea, and constipation. Most standard medications have not helped. I did some research to learn about investigational drugs, which I'd be excited to get to access through a trial."
BW
Gasteroparesis PatientAge: 38
Seralutinib for Pulmonary Arterial Hypertension
Kansas City, Kansas
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Severe Medical Abnormality, Others
Must Be Taking:Seralutinib
300 Participants Needed
Seralutinib for Pulmonary Arterial Hypertension
Kansas City, Kansas
This trial is testing a medication called seralutinib to see if it can help people with a specific type of lung disease (PAH) improve their ability to exercise. The medication works by blocking signals that cause the blood vessels in the lungs to tighten and narrow. Seralutinib is delivered via inhalation and is being developed for patients with pulmonary arterial hypertension. The goal is to see if this can reduce lung pressure and delay worsening of the disease.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis, Hypertension, Others
Must Be Taking:Endothelin Antagonists, PDE5 Inhibitors
390 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Kansas City, Kansas
Researchers are looking for other ways to treat pulmonary arterial hypertension (PAH). Sotatercept is a study medicine that is designed to treat PAH.
A past study, MK-7962-024 (LIGHTRAY) (NCT06664801), learned about the safety and effects of sotatercept in people with PAH. One of the goals of that study was to learn about sotatercept when given at a dose (amount) based on the weight range a person is in (weight-banded doses) compared to when given based on a person's exact weight.
This is an extension study, which means people who took part in MK-7962-024 (LIGHTRAY) may be able to join this study. In this extension study, people will get weight-banded doses of sotatercept. The main goal of this study is to learn about the safety of weight-banded doses of sotatercept and if people tolerate it over a longer period of time.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Not In MK-7962-024, Others
Must Not Be Taking:Activin Inhibitors
130 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Kansas City, Kansas
Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs.
The goal of the study is to learn:
* What happens to different doses of sotatercept in a person's body over time when it is given using weight-banded doses compared to weight-based doses. There may be differences in how the medicine works with the new dosing method (weight-banded dosing) being studied in this trial.
* About the safety of sotatercept and if people tolerate it
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Hypertension, Coronary Artery Disease, Obstructive Sleep Apnea, Others
160 Participants Needed
LTP001 for Pulmonary Arterial Hypertension
Kansas City, Kansas
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Cardiac Abnormalities, Hypersensitivity, Others
Must Be Taking:PAH Therapies
232 Participants Needed
GB002 for Pulmonary Arterial Hypertension
Kansas City, Kansas
This trial will study the long-term effects of GB002 (seralutinib) in patients who were part of an earlier study for Pulmonary Arterial Hypertension (PAH). Seralutinib is a new treatment developed for PAH and has shown better results compared to another treatment in early studies.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Hypertension, Heart Disease, Infections, Others
Must Be Taking:PAH Therapies
74 Participants Needed
Blood Pressure Medication for Chronic Pain
Kansas City, Kansas
The purpose of this study (PASSION study) is to monitor symptoms of chronic pain before and after 2 weeks of a standard drug commonly used to treat elevated blood pressure compared with 2 weeks of placebo (crossover design) so that we may better understand how blood pressure affects your level of pain. This study is not testing an experimental drug.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1
Age:40 - 79
Key Eligibility Criteria
Disqualifiers:Renal Failure, Neurological Disease, Cancer, Others
Must Not Be Taking:Antihypertensives, Insulin, NSAIDs
36 Participants Needed
Renal Denervation for High Blood Pressure
Kansas City, Missouri
This trial is testing a treatment that uses ultrasound waves to target kidney nerves to help lower blood pressure. It is aimed at patients whose high blood pressure does not improve with standard medications. The goal is to see if this method is safe and effective for these patients.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Type I Diabetes, Uncontrolled Type II Diabetes, Severe Cardiovascular Event, Others
Must Be Taking:Antihypertensives
300 Participants Needed
AGN-193408 SR for Glaucoma
Kansas City, Missouri
This trial is testing a new medication called AGN-193408 SR to see if it can safely lower eye pressure in people with open-angle glaucoma or ocular hypertension.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Ocular Trauma, Herpetic Ocular Diseases, Others
Must Not Be Taking:Corticosteroids
96 Participants Needed
Vicadrostat + Empagliflozin for Type 2 Diabetes and Hypertension
Kansas City, Missouri
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin.
Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine.
Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo.
Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Heart Failure, Atrial Fibrillation, Others
Must Be Taking:Antihypertensives, Antidiabetics, Cardiovascular Drugs
11800 Participants Needed
Know someone looking for new options?
Spread the word